S100A8 and atherosclerosis: One important challenge in using S100A8/A9 as a therapeutic target in chronic wounds is the relative abundance of this protein in human circulation, with median levels of approximately 5 mg/L in healthy individuals and up to 15 mg/L in atherosclerosis patients [40].